Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
Development of the ulcerative colitis project PN-943 continues.
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Novel approaches including gene editing are creeping towards approval.